Stallergenes to create Australian subsidiary on back of Oralair approval
This article was originally published in Scrip
Executive Summary
European biopharmaceutical company Stallergenes is to create a subsidiary in Australia following the approval of its grass pollen sublingual immunotherapy tablet Oralair in adult and paediatric indications there, with further global expansion slated for the longer term.